|
Taysha Gene Therapies Inc (NASDAQ: TSHA) |
|
Taysha Gene Therapies Inc
TSHA's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Taysha Gene Therapies Inc 's sales fell
by -62.33 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1100
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 13.31 %
Taysha Gene Therapies Inc net loss decreased from $-117 millions, to $-26 millions in III. Quarter 2024,
• More on TSHA's Growth
|
|
Taysha Gene Therapies Inc realized a net loss in trailing twelve months.
Taysha Gene Therapies Inc realized cash reduction of $ -0.02 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 41.06.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.55.
• More on TSHA's Valuation
|
|
|
|
|
Taysha Gene Therapies Inc realized net loss in trailing twelve months.
Taysha Gene Therapies Inc realized cash outflow of $ -0.02per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 41.06.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.55.
Taysha Gene Therapies Inc Price to Book Ratio is at 4.58 lower than Industry Avg. of 471.52. and higher than S&P 500 Avg. of 0.01
• More on TSHA's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com